# A Study of Two Formulations of Ixekizumab in Healthy Participants

> **NCT04259346** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 245 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ixekizumab

## Key facts

- **NCT ID:** NCT04259346
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-05
- **Primary completion:** 2021-02-19
- **Final completion:** 2021-02-19
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2022-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04259346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04259346, "A Study of Two Formulations of Ixekizumab in Healthy Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04259346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*